Comparison of Contemporary Drug-Eluting Stents in Patients Undergoing Complex High-Risk Indicated Procedures

[1]  W. O’Neill,et al.  Sex‐related difference in the use of percutaneous left ventricular assist device in patients undergoing complex high‐risk percutaneous coronary intervention: Insight from the cVAD registry , 2019, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[2]  M. Zwahlen,et al.  Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial , 2019, The Lancet.

[3]  P. Serruys,et al.  Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials , 2019, The Lancet.

[4]  Seung‐Jung Park,et al.  Comparative effectiveness of different contemporary drug-eluting stents in routine clinical practice: a multigroup propensity score analysis using data from the stent-specific, multicenter, prospective registries , 2019, Coronary artery disease.

[5]  K. Seung,et al.  Differential cutoff points and clinical impact of stent parameters of various drug-eluting stents for predicting major adverse clinical events: An individual patient data pooled analysis of seven stent-specific registries and 17,068 patients. , 2019, International journal of cardiology.

[6]  A. Íñiguez,et al.  Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study , 2019, American heart journal.

[7]  G. Stone,et al.  Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease: Meta-Analysis of Randomized Trials , 2018, Circulation.

[8]  M. Stoel,et al.  Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt–chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial , 2018, The Lancet.

[9]  Seung‐Jung Park,et al.  Safety and Effectiveness of Second-Generation Drug-Eluting Stents in Patients With Left Main Coronary Artery Disease. , 2018, Journal of the American College of Cardiology.

[10]  J. Massaro,et al.  Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial , 2017, The Lancet.

[11]  G. Stone,et al.  Coronary balloon angioplasty, stents, and scaffolds , 2017, The Lancet.

[12]  Seung‐Jung Park,et al.  Differential Rates and Clinical Significance of Periprocedural Myocardial Infarction After Stenting or Bypass Surgery for Multivessel Coronary Disease According to Various Definitions. , 2017, JACC. Cardiovascular interventions.

[13]  J. W. Louwerenburg,et al.  Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial , 2016, The Lancet.

[14]  I. Palacios,et al.  Treatment of Higher-Risk Patients With an Indication for Revascularization: Evolution Within the Field of Contemporary Percutaneous Coronary Intervention , 2016, Circulation.

[15]  T. Bass.  High-Risk Percutaneous Coronary Interventions in Modern Day Clinical Practice: Current Concepts and Challenges. , 2015, Circulation. Cardiovascular interventions.

[16]  A. Neskovic,et al.  A first-in-man clinical evaluation of Ultimaster, a new drug-eluting coronary stent system: CENTURY study. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[17]  G. Stone,et al.  Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. , 2015, Journal of the American College of Cardiology.

[18]  Deepak L. Bhatt,et al.  Percutaneous circulatory assist devices for high-risk coronary intervention. , 2015, JACC. Cardiovascular interventions.

[19]  S. Saito,et al.  A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial , 2014, European heart journal.

[20]  Hyun-Jae Kang,et al.  Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. , 2014, European heart journal.

[21]  R. Wilensky,et al.  Five-year follow-up of patients treated for coronary artery disease in the face of an increasing burden of co-morbidity and disease complexity (from the NHLBI Dynamic Registry). , 2014, The American journal of cardiology.

[22]  M. Mack,et al.  Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). , 2013, Journal of the American College of Cardiology.

[23]  Lane F Burgette,et al.  A tutorial on propensity score estimation for multiple treatments using generalized boosted models , 2013, Statistics in medicine.

[24]  Seung‐Jung Park,et al.  Impact of ad hoc percutaneous coronary intervention with drug-eluting stents in angina patients. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[25]  D. Holmes,et al.  Drug-eluting coronary-artery stents. , 2013, The New England journal of medicine.

[26]  M. Jeong,et al.  Outcomes After Unrestricted Use of Everolimus-Eluting and Sirolimus-Eluting Stents in Routine Clinical Practice: A Multicenter, Prospective Cohort Study , 2012, Circulation. Cardiovascular interventions.

[27]  G. Stone,et al.  Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.

[28]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[29]  Volker Klauss,et al.  Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. , 2010, The New England journal of medicine.

[30]  M. Jeong,et al.  Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgi , 2010, Journal of the American College of Cardiology.

[31]  M. Jeong,et al.  Duration of dual antiplatelet therapy after implantation of drug-eluting stents. , 2010, The New England journal of medicine.

[32]  C. Yancy,et al.  Thrombosis in Coronary Drug-Eluting Stents: Report From the Meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7–8, 2006* , 2007, Circulation.

[33]  P D Cleary,et al.  Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. , 2001, Journal of clinical epidemiology.

[34]  F. Eberli,et al.  revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial , 2022 .